AsiaLand

Based in China, AsiaLand is a developer specializing in innovative biotherapeutic technologies aimed at enhancing healthcare outcomes through advanced treatment solutions. AsiaLand, founded in 2009, operates as a biotherapeutic technology developer based in Changzhou, China. The company has completed one deal to date, with its most recent deal occurring on January 5, 2026. The founder's history and details about previous ventures are not available.

AsiaLand specializes in advanced biotherapeutic technologies, focusing on the development and commercialization of innovative treatments for a variety of medical conditions. The company offers core products that include biologics and therapies designed to address chronic diseases and regenerative medicine, utilized by healthcare providers, hospitals, and research institutions across Asia, Europe, and North America. The revenue model of AsiaLand is centered around B2B transactions with healthcare providers and research institutions. Clients engage in direct procurement agreements to purchase therapeutic products, and the company also seeks partnerships for joint ventures or research projects to enhance its revenue streams.

Due to the specialized nature of its flagship products, premium pricing is anticipated, allowing AsiaLand to maintain strategic relationships within the healthcare ecosystem. In January 2026, AsiaLand raised an undisclosed amount of venture funding from new investor Xinhui Venture Capital. The company plans to leverage this funding to design and launch new products, with specific upcoming offerings expected to address unmet healthcare needs. AsiaLand is also targeting expansion into new markets across Europe and North America by the end of 2026, enhancing its global footprint and reaching a wider client base.